The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma.
Robert John Motzer
Consultant or Advisory Role - Pfizer
Research Funding - AVEO; GlaxoSmithKline; Pfizer
Timothy Eisen
Consultant or Advisory Role - Astellas Pharma (U); AVEO (U)
Stock Ownership - AstraZeneca
Research Funding - Bayer; GlaxoSmithKline; Pfizer
Thomas E. Hutson
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Honoraria - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Research Funding - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Cezary Szczylik
Consultant or Advisory Role - AVEO
Mizue Krygowski
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Andrew Louis Strahs
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Brooke Esteves
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Andrew P. Krivoshik
Employment or Leadership Position - Astellas Pharma
Stock Ownership - Abbott Laboratories
Anna Berkenblit
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Dmitry Nosov
No relevant relationships to disclose